INNOVENT BIO (01801) saw its shares drop more than 8% in early trading. At the time of writing, the stock was down 7.61% to HK$80.1, with a turnover of HK$845 million. The decline follows news that the company's founder, Chairman, and CEO, Dechao Yu, sold 1.353 million shares on May 11, 2026, at an average price of HK$89.362 per share, raising approximately HK$121 million. Following this transaction, his shareholding decreased to 7.49%, though he remains the largest single shareholder. China Post Securities noted that INNOVENT BIO achieved its first full-year profit in 2025, signaling that its business model has proven successful and the company has officially entered a profitable era. The gross profit margin benefited from economies of scale and improved production efficiency, increasing by 2.3 percentage points year-over-year to 87.2%. Revenue growth was robust, while the sales and administrative expense ratio decreased by 2.9 percentage points year-over-year to 48.0%. EBITDA surged 384% year-over-year to RMB 1.99 billion. Cash and cash equivalents stood at RMB 24.3 billion, equivalent to approximately US$3.5 billion, providing a solid foundation for long-term development.